NCT07418450Recruiting
Discrimination of N2a and N2b by EBUS-TBNA: is a Change of the Needle Necessary?
Discrimination of N2a and N2b by EBUS-TBNA: is a Needle Change Necessary? - a Prospective Pilot Study
Source: ClinicalTrials.gov · Last updated 18 Feb 2026
Brief summary (registry, in English)
During EBUS staging in patients with mediastinal lymphadenopathy, it is planned to perform a first round of staging with change of the needle between all lymph nodes and a second round of staging without change of the needle.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Feb 2026
- Start date
- 5 Nov 2025
- Primary completion date
- 31 May 2027
- Lead sponsor
- University of Vienna
- Diseases
- Lung cancer
- NCT number
- NCT07418450
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 5 Nov 2025 to the primary completion date, 31 May 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- \-
Who the study is looking for
- Pulmonary lesion suspicious for lung cancer or histologically confirmed lung cancer
- indication for mediastinal staging
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna Coordinator of this site? Confirm its status | Vienna | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.